AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, will attend theJefferies Global Healthcare ConferenceinLondon from 17 to 20 November 2025.
The AdvanCell team – Andrew Adamovich (CEO), Anna Karmann (CMO), Matthew Vincent (CBO), Simon Puttick (CSO) and Dayle Hogg (COO) – will discuss the company’s clinical and corporate progress, including the encouraging Phase 1b trial results for 212Pb-ADVC001, recently presented at ESMO, as well as the upcoming Phase 2 expansion in metastatic castration-resistant (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), and progress on the company’s US expansion.
“It’s an incredibly exciting time for AdvanCell,” said Andrew Adamovich, CEO of AdvanCell. “We are very encouraged by the promising Phase 1 data for ADVC001. We are expanding our US operations and manufacturing capabilities to support the next stage of development for our company, our lead asset and our pipeline. We look forward to engaging with investors and partners in London to discuss these important developments.”
